Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CENTURY THERAPEUTICS, INC.

(IPSC)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/10/2021 09/13/2021 09/14/2021 09/15/2021 09/16/2021 Date
26.98(c) 27.72(c) 28.37(c) 28.8(c) 29.25(c) Last
111 558 92 229 141 229 147 673 159 868 Volume
+6.30% +2.74% +2.34% +1.52% +1.56% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -85,4 M - -
Net cash position 2021 348 M - -
P/E ratio 2021 -11,0x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -101 M - -
Net cash position 2022 248 M - -
P/E ratio 2022 -16,5x
Yield 2022 -
Capitalization 1 591 M 1 591 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 121
Free-Float 88,8%
More Financials
Company
Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic, pluripotent stem cells (iPSC)-derived natural killer (NK) and T cell therapies to create products for the treatment of both solid tumor and hematological malignancies. Its Allo-Evasion technology is intended to prevent rejection of cell products by the host immune system, and manufacturing... 
More about the company
All news about CENTURY THERAPEUTICS, INC.
08/12CENTURY THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Busines..
PU
08/12CENTURY THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regu..
AQ
08/12CENTURY THERAPEUTICS : Earnings Flash (IPSC) CENTURY THERAPEUTICS Reports Q2 Los..
MT
08/12CENTURY THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Busines..
AQ
08/12Century Therapeutics, Inc. Announces Unaudited Consolidated Earnings Results ..
CI
07/13CENTURY THERAPEUTICS : SVB Leerink Initiates Coverage on Century Therapeutics Wi..
MT
07/13CENTURY THERAPEUTICS : JPMorgan Starts Century Therapeutics at Overweight With $..
MT
07/13CENTURY THERAPEUTICS : BofA Securities Starts Century Therapeutics at Buy With $..
MT
07/13CENTURY THERAPEUTICS : Piper Sandler Starts Century Therapeutics at Overweight W..
MT
06/25CENTURY THERAPEUTICS, INC. : Amendments to Articles of Inc. or Bylaws; Change in..
AQ
More news
News in other languages on CENTURY THERAPEUTICS, INC.

- No features available -

More news
Analyst Recommendations on CENTURY THERAPEUTICS, INC.
More recommendations
Chart CENTURY THERAPEUTICS, INC.
Duration : Period :
Century Therapeutics, Inc. Technical Analysis Chart | IPSC | US15673T1007 | MarketScreener
Technical analysis trends CENTURY THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 29,25 $
Average target price 36,25 $
Spread / Average Target 23,9%
EPS Revisions
Managers and Directors
Osvaldo Flores Chief Executive Officer & Director
Douglas Carr Vice President-Finance & Operations
Joseph Jimenez Chairman
Hyam I. Levitsky President-Research & Development
Cynthia M. Butitta Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CENTURY THERAPEUTICS, INC.0.00%1 591
MODERNA, INC.321.80%175 368
LONZA GROUP AG34.92%61 973
IQVIA HOLDINGS INC.43.91%49 541
CELLTRION, INC.-25.63%31 848
SEAGEN INC.-12.32%27 670